October’s oncology coverage highlighted new treatment options in rectal, breast, and prostate cancers, alongside longer-term survival findings and concerns about reduced-frequency immunotherapy.
|Articles|September 24, 2021
Daily Medication Pearl: Ribociclib (Kisqali) for Breast Cancer
Author(s)Saro Arakelians, PharmD
Ribociclib is an inhibitor of cyclin-dependent kinase 4 and 6 and causes tumor growth inhibition.
Advertisement
Medication Pearl of the Day: Ribociclib (Kisqali)
Ribociclib is a kinase inhibitor indicated for breast cancer.
Insight:
- Ribociclib tablets are taken orally, with or without food, in combination with an aromatase inhibitor or Fulvestrant.
- Recommended starting dose: 600 mg orally taken once daily, with or without food, for 21 consecutive days followed by 7 days off treatment.
- Dosage comes in 200 mg tablet format.
- Mechanism of action: Ribociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6 and causes tumor growth inhibition.
- Adverse events include neutropenia, nausea, infections, fatigue, diarrhea, leukopenia, vomiting, alopecia, headache, constipation, rash, and cough.
- Interactions: Avoid concomitant use of ribociclib with strong CYP3A inhibitors. Avoid concomitant use of ribociclib with strong CYP3A inducers. Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines.
- Manufactured by: Novartis
SOURCE:
Advertisement
Related to this article
ESMO 2026 breast cancer updates show ribociclib boosts survival, while immunotherapy and extended endocrine therapy improve end points without longer overall survival.
In an interview with Pharmacy Times, Danielle Roman, PharmD, BCOP, FHOPA, discusses NCCN breast cancer guideline updates involving ESR1 mutation testing, targeted therapies, and pharmacists’ roles in monitoring, patient counseling, and treatment access.
Specialty pharmacy liaisons improve breast cancer care by easing access barriers, managing side effects, boosting adherence, and navigating new therapies and policies.
Six-year NATALEE data show adjuvant ribociclib (Kisqali) plus endocrine therapy improves overall survival in high-risk HR+/HER2- early breast cancer, with pharmacist-led monitoring.
Pharmacists can help care for patients receiving breast cancer endocrine therapy by identifying fracture risk early and supporting appropriate bone-directed treatment throughout survivorship.
Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Happens Before the First Dose? 5 Steps That Shape Lung Cancer Treatment
2
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
Nicotine Vaping Linked to Lower Vascular Function in Young Adults
4
Full IDWeek Data Highlights 31-Valent Pneumococcal Conjugate Vaccine Candidate in Adults
5